文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study.

作者信息

Macaluso Fabio Salvatore, Principi Mariabeatrice, Facciotti Federica, Contaldo Antonella, Todeschini Alessia, Saibeni Simone, Bezzio Cristina, Castiglione Fabiana, Nardone Olga Maria, Spagnuolo Rocco, Fantini Massimo Claudio, Riguccio Gaia, Conforti Simone, Caprioli Flavio, Viganò Chiara, Felice Carla, Fiorino Gionata, Correale Carmen, Bodini Giorgia, Milla Monica, Scardino Giulia, Vernero Marta, Desideri Federico, Bossa Fabrizio, Guerra Maria, Ventimiglia Marco, Casà Angelo, Rizzo Giuseppe, Orlando Ambrogio

机构信息

IBD Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.

Gastroenterology Department, "Aldo Moro" University, Bari, Italy.

出版信息

Inflamm Bowel Dis. 2024 May 2;30(5):854-858. doi: 10.1093/ibd/izad118.

DOI:10.1093/ibd/izad118
PMID:37390400
Abstract
摘要

相似文献

[1]
Lack of Seroconversion Following COVID-19 Vaccination Is an Independent Risk Factor for SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: Data from ESCAPE-IBD, an IG-IBD Study.

Inflamm Bowel Dis. 2024-5-2

[2]
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study).

Gastroenterol Hepatol. 2024

[3]
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study).

Gastroenterol Hepatol. 2024-10

[4]
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.

Aliment Pharmacol Ther. 2025-1

[5]
Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease.

Clin Gastroenterol Hepatol. 2024-7

[6]
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.

Eur J Cancer. 2021-12

[7]
Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients.

Inflamm Bowel Dis. 2021-10-20

[8]
SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis.

J Chin Med Assoc. 2022-4-1

[9]
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.

EBioMedicine. 2024-10

[10]
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.

Gut. 2021-10

引用本文的文献

[1]
Causal relationship between COVID-19, vaccination, and 20 digestive diseases: a comprehensive two-sample Mendelian randomization study.

Virol J. 2025-6-30

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索